Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective


BACKGROUND The aim of this study was to project health-economic outcomes relevant to the German setting for the addition of pioglitazone to existing treatment regimens in patients with type 2 diabetes, evidence of macrovascular disease and at high risk of cardiovascular events. METHODS Event rates corresponding to macrovascular outcomes from the… (More)
DOI: 10.1186/1478-7547-7-9


5 Figures and Tables